Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $36,624.00 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 1,635 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $22.40, for a total value of $36,624.00. Following the sale, the chief financial officer directly owned 85,034 shares of the company’s stock, valued at approximately $1,904,761.60. This trade represents a 1.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Howard Horn also recently made the following trade(s):

• On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30.
• On Monday, February 2nd, Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16.
• On Wednesday, December 10th, Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78.

Ultragenyx Pharmaceutical Trading Down 1.6%

RARE stock opened at $21.46 on Friday. The firm’s 50-day moving average price is $23.30 and its two-hundred day moving average price is $29.14. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -3.67 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.41 and a 12-month high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.39) earnings per share. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on RARE shares. Robert W. Baird dropped their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Leerink Partners cut their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Wedbush reissued a “neutral” rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Guggenheim cut their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Finally, Bank of America reduced their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. Sixteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds have recently made changes to their positions in RARE. Covestor Ltd increased its position in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares in the last quarter. Huntington National Bank grew its stake in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of Ultragenyx Pharmaceutical by 1.8% in the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after acquiring an additional 404 shares during the last quarter. Xponance Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 3.1% during the third quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 406 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 434 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.